Right now it is LymPro and the Diagnostic Spin Off that moves the stock price. But before long, Eltoprazine's phase 2b trial will start effecting the stock price. (Maybe in March) ESS will move us in Q2. MANF will start effecting the stock price once RP starts it's clinical trial in a year. In the mean time, MANF updates will make us feel better about our future, but won't move the price until it gets further along, IMHO.